Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
Hematologic Malignancies · Waldenstroms Macroglobulinaemia · Non-Hodgkins Lymphoma · Chronic Lymphocytic Leukaemia
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 2
- Patients
- 490 (planned)
- Started
- Apr 5, 2021
- Main results expected
- Jan 4, 2029
- Fully finished
- Jan 4, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Part 1: Number of participants experiencing dose-limiting toxicities (DLTs)
Measured over: Up to ~56 days (Cycles 1-2, cycle = 28 days)
Part 1: Number of participants experiencing adverse events (AEs)
Measured over: Up to ~71 months
Part 1: Number of participants discontinuing study treatment due to AEs
Measured over: Up to ~42 months
Part 2: Objective Response Rate (ORR) per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria 2018 as assessed by independent central review (ICR)
Measured over: Up to ~61 months
Part 2: ORR per Lugano criteria 2014 as assessed by ICR
Measured over: Up to ~61 months
Part 2: ORR per International Workshop on Waldenström's Macroglobulinemia (IWWM) criteria 2014 as assessed by ICR
Measured over: Up to ~71 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04728893 · record last updated 2026-10-27 · checked 2026-11-09 15:47 UTC